As AstraZeneca Cuts Back In The U.S., It’s Full Steam Ahead In China
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca continues to invest in higher-growth markets like China by acquiring a privately owned injectables generics manufacturer in Guangdong province.